CCL26 and COVID-19: However, the robust study design and statistical analysis as well as the consistencies with previous studies, such as the upregulation in patients with COVID-19 of ACE2 [22], FGF21 [41], CCL26 [54,55] and VWF [89,90] among others, suggest the potential validation of these novel findings.